List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Antibody Drug Conjugate Revenue
1.4 Market Analysis by Type
1.4.1 Global Antibody Drug Conjugate Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Adcetris
1.4.3 Kadcyl
1.5 Market by Application
1.5.1 Global Antibody Drug Conjugate Market Share by Application: 2022-2027
1.5.2 Hospital
1.5.3 Pharmaceutical Company
1.5.4 Research Institutions
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Antibody Drug Conjugate Market
1.8.1 Global Antibody Drug Conjugate Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Antibody Drug Conjugate Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Antibody Drug Conjugate Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Antibody Drug Conjugate Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Antibody Drug Conjugate Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Antibody Drug Conjugate Sales Volume Market Share by Region (2016-2021)
3.2 Global Antibody Drug Conjugate Sales Revenue Market Share by Region (2016-2021)
3.3 North America Antibody Drug Conjugate Sales Volume
3.3.1 North America Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.3.2 North America Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Antibody Drug Conjugate Sales Volume
3.4.1 East Asia Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Antibody Drug Conjugate Sales Volume (2016-2021)
3.5.1 Europe Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Antibody Drug Conjugate Sales Volume (2016-2021)
3.6.1 South Asia Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Antibody Drug Conjugate Sales Volume (2016-2021)
3.7.1 Southeast Asia Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Antibody Drug Conjugate Sales Volume (2016-2021)
3.8.1 Middle East Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Antibody Drug Conjugate Sales Volume (2016-2021)
3.9.1 Africa Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Antibody Drug Conjugate Sales Volume (2016-2021)
3.10.1 Oceania Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Antibody Drug Conjugate Sales Volume (2016-2021)
3.11.1 South America Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.11.2 South America Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Antibody Drug Conjugate Sales Volume (2016-2021)
3.12.1 Rest of the World Antibody Drug Conjugate Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Antibody Drug Conjugate Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Antibody Drug Conjugate Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Antibody Drug Conjugate Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Antibody Drug Conjugate Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Antibody Drug Conjugate Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Antibody Drug Conjugate Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Antibody Drug Conjugate Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Antibody Drug Conjugate Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Antibody Drug Conjugate Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Antibody Drug Conjugate Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Antibody Drug Conjugate Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Antibody Drug Conjugate Sales Volume Market Share by Type (2016-2021)
14.2 Global Antibody Drug Conjugate Sales Revenue Market Share by Type (2016-2021)
14.3 Global Antibody Drug Conjugate Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Antibody Drug Conjugate Consumption Volume by Application (2016-2021)
15.2 Global Antibody Drug Conjugate Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Antibody Drug Conjugate Business
16.1 Seattle Genetics/Takeda
16.1.1 Seattle Genetics/Takeda Company Profile
16.1.2 Seattle Genetics/Takeda Antibody Drug Conjugate Product Specification
16.1.3 Seattle Genetics/Takeda Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Roche
16.2.1 Roche Company Profile
16.2.2 Roche Antibody Drug Conjugate Product Specification
16.2.3 Roche Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 ImmunoGen
16.3.1 ImmunoGen Company Profile
16.3.2 ImmunoGen Antibody Drug Conjugate Product Specification
16.3.3 ImmunoGen Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Immunomedics
16.4.1 Immunomedics Company Profile
16.4.2 Immunomedics Antibody Drug Conjugate Product Specification
16.4.3 Immunomedics Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Pfizer
16.5.1 Pfizer Company Profile
16.5.2 Pfizer Antibody Drug Conjugate Product Specification
16.5.3 Pfizer Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Celldex Therapeutics
16.6.1 Celldex Therapeutics Company Profile
16.6.2 Celldex Therapeutics Antibody Drug Conjugate Product Specification
16.6.3 Celldex Therapeutics Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Millennium Pharmaceuticals
16.7.1 Millennium Pharmaceuticals Company Profile
16.7.2 Millennium Pharmaceuticals Antibody Drug Conjugate Product Specification
16.7.3 Millennium Pharmaceuticals Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Bayer HealthCare
16.8.1 Bayer HealthCare Company Profile
16.8.2 Bayer HealthCare Antibody Drug Conjugate Product Specification
16.8.3 Bayer HealthCare Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Mersana Therapeutics
16.9.1 Mersana Therapeutics Company Profile
16.9.2 Mersana Therapeutics Antibody Drug Conjugate Product Specification
16.9.3 Mersana Therapeutics Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Heidelberg Pharma
16.10.1 Heidelberg Pharma Company Profile
16.10.2 Heidelberg Pharma Antibody Drug Conjugate Product Specification
16.10.3 Heidelberg Pharma Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Oxford BioTherapeutics
16.11.1 Oxford BioTherapeutics Company Profile
16.11.2 Oxford BioTherapeutics Antibody Drug Conjugate Product Specification
16.11.3 Oxford BioTherapeutics Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Takeda Pharmaceutical Company Limited
16.12.1 Takeda Pharmaceutical Company Limited Company Profile
16.12.2 Takeda Pharmaceutical Company Limited Antibody Drug Conjugate Product Specification
16.12.3 Takeda Pharmaceutical Company Limited Antibody Drug Conjugate Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Antibody Drug Conjugate Manufacturing Cost Analysis
17.1 Antibody Drug Conjugate Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Antibody Drug Conjugate
17.4 Antibody Drug Conjugate Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Antibody Drug Conjugate Distributors List
18.3 Antibody Drug Conjugate Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Antibody Drug Conjugate (2022-2027)
20.2 Global Forecasted Revenue of Antibody Drug Conjugate (2022-2027)
20.3 Global Forecasted Price of Antibody Drug Conjugate (2016-2027)
20.4 Global Forecasted Production of Antibody Drug Conjugate by Region (2022-2027)
20.4.1 North America Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.3 Europe Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.7 Africa Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.9 South America Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Antibody Drug Conjugate Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Antibody Drug Conjugate by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Antibody Drug Conjugate by Country
21.2 East Asia Market Forecasted Consumption of Antibody Drug Conjugate by Country
21.3 Europe Market Forecasted Consumption of Antibody Drug Conjugate by Countriy
21.4 South Asia Forecasted Consumption of Antibody Drug Conjugate by Country
21.5 Southeast Asia Forecasted Consumption of Antibody Drug Conjugate by Country
21.6 Middle East Forecasted Consumption of Antibody Drug Conjugate by Country
21.7 Africa Forecasted Consumption of Antibody Drug Conjugate by Country
21.8 Oceania Forecasted Consumption of Antibody Drug Conjugate by Country
21.9 South America Forecasted Consumption of Antibody Drug Conjugate by Country
21.10 Rest of the world Forecasted Consumption of Antibody Drug Conjugate by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
